Search results for "Adjuvant"

showing 10 items of 733 documents

Uterine leiomyoma metastasis as a first sign of breast cancer

1998

Uterine metastases from extragenital cancer are rarely reported in the literature. More frequently, the female genital tract is involved by direct extension from an adjacent pelvic organ. A 37-year-old woman had a myoma of the uterine wall and hypermenorrhea. The mass was laparoscopically enucleated, and frozen section examination was performed because it was macroscopically suspicious for sarcomatoid degeneration. The final diagnosis was metastatic carcinoma in the uterus of probable breast origin.

Adultmedicine.medical_specialtyPathologyUterusAntineoplastic AgentsBreast NeoplasmsMetastatic carcinomaMetastasisFatal OutcomeBreast cancermedicineHumansGynecologyFrozen section procedureUterine leiomyomaLeiomyomabusiness.industryBiopsy NeedleObstetrics and GynecologyCancerMyomamedicine.diseaseImmunohistochemistrymedicine.anatomical_structureChemotherapy AdjuvantLymphatic MetastasisUterine NeoplasmsFemaleLaparoscopyRadiotherapy AdjuvantbusinessThe Journal of the American Association of Gynecologic Laparoscopists
researchProduct

The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer.

2016

Introduction Prostatic Specific Antigen (PSA), Bacillus Calmette-Guerin (BCG) increase after intravesical BCG has been reported. The need of prostate biopsy in these patients is object of debate. The aim of our study was to evaluate the effect of intravesical therapy on PSA after transurethral resection (TUR) of nonmuscle-invasive bladder cancer (NMIBC). Materials and methods Patients undergoing intravesical chemotherapy or immunotherapy for NMIBC were entered. PSA was measured before TUR, before the first and after the sixth instillation, 30 and 90 days after the last instillation. Patients with PSA ≥4 ng/ml or palpable prostate nodule were excluded. Results Out of 130 patients, 105 were e…

Adultmedicine.medical_specialtyProstate biopsymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic Agents03 medical and health sciencesProstate cancer0302 clinical medicineAdjuvants ImmunologicBiopsyIntravesical instillation Prostate cancer PSAmedicineAdjuvant therapyCombined Modality TherapyHumansNeoplasm InvasivenessAgedAged 80 and overChemotherapyBladder cancermedicine.diagnostic_testbusiness.industryGeneral MedicineImmunotherapyMiddle AgedProstate-Specific Antigenmedicine.diseaseCombined Modality TherapyAdministration IntravesicalUrinary Bladder Neoplasms030220 oncology & carcinogenesisBCG VaccinebusinessUrologia
researchProduct

Is intravesical instillation of hyaluronic acid and chondroitin sulfate useful in preventing recurrent bacterial cystitis? A multicenter case control…

2015

Abstract Objective Urinary tract infections (UTIs) are common in the female population and, over a lifetime, about half of women have at least one episode of UTI requiring antibiotic therapy. The aim of the current study was to compare two different strategies for preventing recurrent bacterial cystitis: intravesical instillation of hyaluronic acid (HA) plus chondroitin sulfate (CS), and antibiotic prophylaxis with sulfamethoxazole plus trimethoprim. Materials and methods This was a retrospective review of two different cohorts of women affected by recurrent bacterial cystitis. Cases (experimental group) were women who received intravesical instillations of a sterile solution of high concen…

Adultmedicine.medical_specialtyRecurrent bacterial cystitismedicine.drug_classUrinary systemCystitiAntibioticsUrinalysislcsh:Gynecology and obstetricsGastroenterologyantibioticsantibiotics; chondroitin sulfate; cystitis; hyaluronic acidchemistry.chemical_compoundAdjuvants ImmunologicRecurrenceInternal medicineObstetrics and GynaecologyHyaluronic acidCystitismedicineHumansChondroitin sulfateAntibiotic prophylaxisHyaluronic Acidlcsh:RG1-991antibiotics chondroitin sulfate cystitis hyaluronic acidchondroitin sulfateRetrospective StudiesDose-Response Relationship Drugbusiness.industrySulfamethoxazoleChondroitin SulfatesAntibioticObstetrics and GynecologySettore MED/40 - Ginecologia E OstetriciaTrimethoprimSurgeryAdministration IntravesicalInstillation DrugchemistryUrinary Tract InfectionsDrug Therapy CombinationFemalebusinessmedicine.drugFollow-Up StudiesTaiwanese journal of obstetricsgynecology
researchProduct

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

2018

Abstract Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over the 12 months of adjuvant trastuzumab in PHARE trial (NCT00381901). Methods LVEF assessment was performed every 3 months while patients received trastuzumab and after completion of treatment over the first 2 years and then every 6 months afterwards. The fluctuations of LVEF over time were described and a logistic regression model was performed investigating associated factors to LVEF perfect recovery at baseline value. Results A total of 1631 patients who received 12 months of trastuzumab from PH…

Adultmedicine.medical_specialtySide effectReceptor ErbB-2medicine.medical_treatmentBreast Neoplasms030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciences0302 clinical medicineBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabInternal medicinemedicineHumansIn patientcardiovascular diseasesCardiotoxicityEjection fractionbusiness.industryGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseCardiotoxicityStandard errorChemotherapy AdjuvantEchocardiography030220 oncology & carcinogenesiscardiovascular systemCardiologySurgeryFemalebusinessAdjuvantcirculatory and respiratory physiologymedicine.drugFollow-Up StudiesBreast (Edinburgh, Scotland)
researchProduct

Heavy Resistance Training in Breast Cancer Patients Undergoing Adjuvant Therapy.

2019

BACKGROUND AND PURPOSE Adjuvant breast cancer therapy may reduce maximal muscle strength, muscle mass, and functional performance. Although maximal strength training (MST) has the potential to counteract this debilitating outcome and is shown to be superior to low- and moderate-intensity strength training, it is unknown if it can elicit effective adaptations in patients suffering treatment-induced adverse side effects. METHODS Fifty-five newly diagnosed stage I to III breast cancer patients (49 ± 7 yr) scheduled for adjuvant therapy were randomized to MST or a control group. The MST group performed 4 × 4 repetitions of dynamic leg press at approximately 90% of one-repetition maximum (1RM) t…

Adultmedicine.medical_specialtyStrength trainingmedicine.medical_treatmentUrologyPhysical Therapy Sports Therapy and RehabilitationBreast NeoplasmsWalkingMastectomy SegmentalBody Mass IndexQuadriceps Muscle03 medical and health sciences0302 clinical medicineBreast cancerAdjuvant therapyMedicineHumansOrthopedics and Sports MedicineMuscle StrengthAdverse effectLeg pressbusiness.industryResistance Training030229 sport sciencesMiddle AgedPhysical Functional Performancemedicine.diseaseQuadriceps femoris muscleRadiation therapyLower ExtremityThighChemotherapy AdjuvantFemaleRadiotherapy Adjuvantbusinesshuman activitiesBody mass indexMedicine and science in sports and exercise
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct

TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Ye…

2003

Abstract OBJECTIVES: To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy. MATERIALS AND METHODS: Between January 1976 and April 1999, 137 patients with T1G3 TCCB were treated by TUR plus intravesical chemotherapy. Particularly, a sequential combination of mitomycin C (MMC) and epirubicin (EPI) was adopted in 91 patients (66.4%). The main exclusion criteria were concomitant or previous Tis, previous T1G3 TCCB, tumor size greater than 3 centimeters and number of tumors more than 3. TUR was repeated if a superficial tumor recurred. Patients went off study…

Adultmedicine.medical_specialtyTime FactorsUrologyPopulationUrologyIntravesical adjuvant chemotherapyDisease-Free SurvivalSettore MED/24 - UrologiaT1G3 bladder cancermedicineAdjuvant therapyHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureUrinary Bladder NeoplasmsChemotherapy AdjuvantTumor progressionConcomitantDisease ProgressionUrologic Surgical ProceduresNeoplasm Recurrence LocalbusinessConservative treatmentFollow-Up StudiesEpirubicinmedicine.drugEuropean Urology
researchProduct

Modulation of oestrogen excretion profiles by adjuvant chemotherapy in pre- and postmenopausal breast cancer.

1985

Modulation of steroid status by conventional chemotherapy was studied in 31 breast cancer patients receiving CMF and in 31 age-matched breast cancer patients without any therapy, taken as controls. This was achieved through the study of oestrogen excretion profiles using previously identified parameters and referring not only to classical but also to the “other”, namely catechol and unusual, oestrogen metabolites. After CMF treatment the premenopausal patients exhibit a modified excretion pattern, mainly concerning a marked and significant reduction of classical oestrogens, as shown by pattern indices. Because there is evidence that oestriol metabolism is not markedly affected by CMF treatm…

Adultmedicine.medical_specialtyTime FactorschlormethineAdjuvant chemotherapymedicine.medical_treatmentBreast NeoplasmsBiochemistryestriolGas Chromatography-Mass SpectrometrySteroidExcretionEndocrinologyBreast cancerInternal medicineestradiolAntineoplastic Combined Chemotherapy ProtocolsmedicineestrogenHumansStage (cooking)CyclophosphamideChromatography High Pressure LiquidAgedbusiness.industryEstrogensMetabolismMiddle Agedmedicine.diseaseestroneEstrogens CatecholEndocrinologyMethotrexateMetabolic rateAdrenal CortexFemaleFluorouracilMenopausebusinessAfter treatmentJournal of steroid biochemistry
researchProduct

Long-Term Results of Ileocecal Continent Urinary Diversion in Patients Treated With and Without Previous Pelvic Irradiation

2002

Patients who receive pelvic irradiation may require urinary diversion to manage complications resulting from progressive malignancy or radiotherapy. The choice of urinary diversion is an important issue and remains controversial. We characterized the long-term outcome of urinary diversion with a continent ileocecal reservoir in patients who received pelvic irradiation versus those who underwent urinary diversion without previous irradiation.Continent urinary diversion with an ileocecal reservoir (Mainz pouch 1) was performed in 36 irradiated patients in a 9-year period. Morbidity, mortality, the reoperative rate and parameters associated with the surgical procedure were determined at a medi…

Adultmedicine.medical_specialtyUrinary systemmedicine.medical_treatmentUrologyPelvisCystectomyPostoperative ComplicationsRisk FactorsmedicineHumansDerivationRadiation InjuriesAgedUrinary bladderbusiness.industryUrinary diversionUrinary Reservoirs Continentrespiratory systemMiddle AgedCombined Modality TherapySurgerymedicine.anatomical_structureUrinary Bladder NeoplasmsFemaleRadiotherapy AdjuvantPouchbusinessComplicationhuman activitiesContinent Urinary DiversionFollow-Up StudiesThe Journal of Urology
researchProduct

Mitomycin C from birth to adulthood.

2016

Mitomycin C (MMC) intravesical therapy for “superficial” papillary bladder tumors was firstly introduced in the early seventies with promising results. In the following years, several pharmacokinetic studies investigated its mechanism of action to optimize the intravesical administration. Numerous studies confirmed thereafter both the ablative and the prophylactic efficacy and the low toxicity of MMC when intravesically given. In 1984, a complete response rate of 42% in 60 patients not responsive to thiotepa was reported with intravesical MMC at the dose of 40 mg diluted in 40 ml for 8 weeks. In the following decades, many large randomized studies showed the benefit of intravesical prophyla…

Adultmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMitomycinAntibiotics030232 urology & nephrologyUrologyThioTEPASettore MED/24 - Urologia03 medical and health sciencesYoung Adult0302 clinical medicinePharmacokineticsMedicineHumansYoung adultChildComplete responseAntibiotics Antineoplasticbusiness.industryMedicine (all)digestive oral and skin physiologyMitomycin CGeneral MedicineRegimenUrinary Bladder Neoplasms030220 oncology & carcinogenesisUrinary Bladder NeoplasmbusinessAdjuvantHumanmedicine.drugUrologia
researchProduct